The FDA flagged a potential VEGF-related safety concern in its rejection letter for Summit Therapeutics and Akeso’s ivonescimab, drawing scrutiny to the broader bispecific strategy class. The notification raises questions about the viability of new VEGF-linked bispecifics at a time when companies are pursuing multi-target immune engagement. The rejection also underscores how safety signals—even before approval—can reshape development plans, including whether further clinical data collection, dosing modifications, or mechanistic risk mitigation are needed. For the biotech community, the immediate relevance is to program teams evaluating similar VEGF-pathway designs and to investors tracking regulatory readiness for this therapeutic approach.
Get the Daily Brief